Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1030-1031; doi:10.1093/jnci/95.14.1030
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1030-1031, July 16, 2003
© 2003 Oxford University Press

NEWS

Prostate Cancer Prevention Trial Yields Positive Results, But With a Few Cautions

Tom Reynolds

The first 10% of the full text of this article appears below.

The Prostate Cancer Prevention Trial, a randomized placebo-controlled study involving nearly 19,000 men at 221 sites over 10 years, has shown that men who took the drug finasteride reduced their risk of getting prostate cancer by about 25%.

Health officials hailed the trial’s results—the first demonstration of a drug’s ability to prevent this common and widely feared disease—as a resounding success for chemoprevention. But the findings also brought some surprises, including a large caveat for men deciding whether to use finasteride.

The National Cancer Institute-sponsored trial, which began enrolling patients in January 1994, was halted 15 months early after a monitoring committee ruled that the already-robust findings were unlikely to change with further study. Still, 86% of enrolled men completed their 7 years on finasteride or placebo. The results appeared . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J EpidemiolHome page
P. Vineis and M. Berwick
The population dynamics of cancer: a Darwinian perspective
Int. J. Epidemiol., October 1, 2006; 35(5): 1151 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
L. J. Schmidt, H. Murillo, and D. J. Tindall
Gene Expression in Prostate Cancer Cells Treated With the Dual 5 Alpha-Reductase Inhibitor Dutasteride
J Androl, November 1, 2004; 25(6): 944 - 953.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Rosner
Proscar and Propecia--A Therapeutic Perspective
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3096 - 3098.
[Full Text] [PDF]